GT Biopharma doses first patient in GTB-5550 trial, but omits required controls disclosure

Filed May 15, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~2 min read

Key Changes

• high

  Company failed to disclose required evaluation of internal controls over financial reporting for Q1 2026, after reporting effective controls in prior year. SEC rules mandate quarterly disclosure of controls effectiveness and any material changes.

  Controls & Procedures verify on EDGAR →
• high

  GTB-5550 advanced from paused development to FDA IND clearance (January 2026) and first patient dosing (May 2026) in basket trial for B7-H3+ solid tumors. GTB-3650 trial approximately 50% enrolled in AML/MDS patients.

  MD&A: Clinical Programs verify on EDGAR →
• high

  Q1 2026 net loss increased to $2.8M from $0.8M prior year, driven by $1.6M higher SG&A (marketing and legal expenses) and loss of $1M vendor settlement gain. Series L financing raised $4.6M, improving working capital to positive $7.6M.

  MD&A: Financial Results verify on EDGAR →